검색어: neonates (영어 - 몰타어)

neonates and infants
trabi tat-twelid u tfal żgħar

children and neonates:
tfal u trabi:

pharmacokinetic data in neonates is limited.
data farmakokinetika fi trabi tat-twelid hija limitata.

pedea is contraindicated in neonates with:
pedea hija kontra- indikata fi trabi tat- twelid b ’:

currently, no clinical data are available in neonates.
bħalissa, m’hemmx dejta klinika f’ trabi ta’ twelid.

must not be given to premature babies or neonates.
m’għandux jingħata lill-trabi prematuri jew trabi tat-twelid.

use in children (including neonates) < 4 months
l-użu fit-tfal (li jinkludu trabi tat-twelid) ta’ < 4 xhur

it must not be given to premature babies or neonates.
m’għandux jingħata lil trabi prematuri jew lil trabi tat-twelid.

optimark is contraindicated in neonates up to 4 weeks of age.
optimark hu kontraindikat fi trabi tat-twelid sal-età ta’ 4 ġimgħat.

use in children (including neonates) < 4 months of age
l-użu fit-tfal (li jinkludu trabi tat-twelid) ta’ < 4 xhur

benzyl alcohol must not be given to premature babies or neonates.
benzyl alcohol m’ għandux jingħata lil trabi li twieldu qabel iż- żmien jew li għadhom kif twieldu

dosage recommendation for neonates of mothers who are hepatitis b virus carriers
rakkomandazzjonijiet għal trabi tat-twelid ta’ ommijiet li huma carriers tal-virus tal-epatite b

dosage recommendations for neonates born to mothers who are hepatitis b virus carriers
rakkomandazzjonijiet għal trabi tat-twelid ta’ ommijiet li huma carriers tal-virus tal-epatite b

children (including neonates) and adolescents < 16 years of age:
tfal (li jinkludu trabi għadhom jitwieldu) u adoloxxenti < 16-il sena:

dosing recommendations are not available for neonates with a gestational age < 37 weeks.
m’hemmx doża rrakkomandata għal trabi għandhom jitwieldu ta’ < 37 ġimgħa.

if you have cancer. in premature babies or neonates because it contains benzyl alcohol.
jekk inti għandek kanċer. fi trabi li twieldu qabel iż-żmien jew li għadhom kif twieldu għaliex fih il-benzyl alcohol.

in the second study, 186 neonates with respiratory failure received either inomax or placebo.
fit-tieni studju, 186 tarbija tat- twelid b’indeboliment respiratorju irċievew jew inomax jew plaċebo.

as ibuprofen may inhibit platelet aggregation, premature neonates should be monitored for signs of bleeding.
billi ibuprofen jista’ jimpedixxi l-aggregazzjoni ta’ plejtlets, trabi li jkunu twieldu qabel iż-żmien għandhom jiġu sorveljati għal sinjali ta’ fsada.

450 - 600 mg/kg/day in neonates, infants and children weighing less than 20 kg
450 - 600 mg/kg/kuljum fi trabi li għadhom jitwieldu, trabi u tfal li jiżnu anqas minn 20 kg

in neonates with pphn, inomax can improve oxygenation (as indicated by significant increases in pao2).
fi trabi tat-twelid b’pphn, inomax jista’ jtejjeb l- għoti tal-ossiġnu (kif indikat b’żidiet sinifikanti f’pao2).